Table 1.
. Baseline characteristics of the participants.
| Characteristic | BNT162b2 | Half-dose mRNA-1273 |
mRNA-1273 | MVC—COV1901 |
|---|---|---|---|---|
| No. of participants | 83 | 85 | 85 | 85 |
| Sex – no. (%) | ||||
| Female | 53 (64) | 58 (68) | 60 (71) | 57 (67) |
| Male | 30 (36) | 27 (32) | 25 (29) | 28 (33) |
| Age - years | ||||
| Median (IQR) | 35.0 (30.0–44.0) | 35.0 (30.0–45.5) | 37.0 (30.5–44.0) | 39.0 (32.5–44.5) |
| Intervals between first and second doses – days | ||||
| Median (IQR) | 63 (59–71) | 68 (60–71) | 63 (61–71) | 68 (61–71) |
| Intervals between second doses and booster – days | ||||
| Median (IQR) | 138 (126–177) | 140 (128–182) | 138 (127–149) | 138 (131–177) |
| Body-mass index* | 22.6 (20.3–24.8) | 23.5 (21.9–26.3) | 23.1 (21.5–25.8) | 22.2 (20.1–25.5) |
| Comorbidities | ||||
| Cardiovascular disease –no. (%) | 6 (7) | 2 (2) | 10 (12) | 6 (7) |
| Diabetes mellitus –no. (%) | 0 (0) | 1 (1) | 4 (5) | 2 (2) |
| Liver disease –no. (%) | 2 (2) | 3 (4) | 4 (5) | 2 (2) |
| Kidney disease –no. (%) | 0 (0) | 1 (1) | 0 (0) | 1 (1) |
| White blood cell count – per mm3 | ||||
| Median (IQR) | 5900 (5300–7200) | 6500 (5500–7850) | 6500 (5500–7750) | 6000 (5300–7700) |
| Hemoglobin – per g/dl | ||||
| Median (IQR) | 13.8 (13.0–15.1) | 13.7 (13.0–14.7) | 13.5 (12.7–14.7) | 13.7 (12.8–14.6) |
| Platelet count – 103 per mm3 | ||||
| Median (IQR) | 272 (232–311) | 282 (240–334) | 278 (247–310) | 263 (233–311) |
| AST – U/liter | ||||
| Median (IQR) | 18 (14–23) | 17 (13–20) | 17 (14–21) | 17 (14–21) |
| ALT – U/liter | ||||
| Median (IQR) | 15 (10–24) | 15 (11–22) | 16 (11–23) | 16 (10–21) |
IQR= interquartile range. AST=aspartate aminotransferase. ALT=alanine aminotransferase.
* Body-mass index is the weight in kilogram divided by the square of the height in meters.